Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 14/20 | 0.53 |
| ▸ | JAK2 | O60674 | 10/20 | 0.53 |
| ▸ | JAK1 | P23458 | 7/20 | 0.53 |
| ▸ | AKT2 | P31751 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009292 | 0.89 | AKT1 (0.52) | AKT1JAK3JAK2JAK1AKT2 | |
| SCHEMBL12696540 | 0.86 | JAK1 (0.55) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL30009218 | 0.84 | JAK1 (0.64) | AKT1JAK3JAK1AKT2PBK | |
| SCHEMBL1076358 | 0.82 | JAK3 (0.64) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL30009369 | 0.81 | JAK3 (0.71) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL16026477 | 0.81 | AKT2 (0.59) | AKT1AKT2PBK | |
| SCHEMBL30009288 | 0.81 | AKT2 (0.57) | AKT1JAK3JAK2JAK1AKT2 | |
| SCHEMBL30009611 | 0.80 | JAK1 (0.64) | JAK3JAK2JAK1TYK2KCNH2 | |
| SCHEMBL10277501 | 0.80 | AKT1 (0.50) | AKT1JAK3JAK2JAK1AKT2 | |
| SCHEMBL27879392 | 0.79 | AKT1 (0.57) | AKT1JAK3JAK1AKT2PBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | AKT1 102/4885JAK3 129/4885JAK2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.